This little girl shares a very special friendship with two 15-foot pythons
This little girl shares a very special friendship with two 15-foot pythons
In a new report published today at Web Summit 2020, Impossible Foods is serving up fresh insight on COVID-19’s extraordinary impact on the company’s operations and workforce.
"To address the unforeseen increase in costs from our suppliers, we reluctantly must raise pricing on all products," the Nov. 26 letter to the chipmakers customers said. Volkswagen AG said Friday that a global chip supply shortage could lead to interruptions in automobile production in China.
Next year is shaping up to be a humanitarian catastrophe and rich countries must not trample poor countries in a "stampede for vaccines" to combat the coronavirus pandemic, top U.N. officials told the 193-member U.N. General Assembly on Friday. World Food Programme (WFP) chief David Beasley and World Health Organization (WHO) head Tedros Adhanom Ghebreyesus spoke during a special meeting on COVID-19, which emerged in China late last year and has so far infected 65 million globally.
The "Solid State Battery: Global Markets" report has been added to ResearchAndMarkets.com's offering.
The "Automotive Infotainment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The Army Corps of Engineers reversed course on an Obama-era proposal to charge for water drawn from reservoirs the Corps manages, North Dakota’s attorney general said Friday. Attorneys general from a dozen Western and Plains states sent a letter last year to the Trump administration asking that the proposal be withdrawn. Republican North Dakota Attorney General Wayne Stenehjem headed the effort, which was backed by attorneys general from Alaska, Arizona, Colorado, Idaho, Montana, New Mexico, Oregon, South Dakota, Utah, Washington and Wyoming.
The economic recovery will be 'pretty uncomfortable' for the next couple of months, according to Moody's Analytics Chief Economist Mark Zandi, as new restrictions are implemented to control the spread of the pandemic.
Can drinking actually help productivity? 'Another Round' and 'Fantastic Beasts 3' star Mads Mikkelsen discusses his new film and the secret to pretending to be drunk.
Mariah Carey hit number two with All I Want for Christmas is You, but was beaten by Ariana Grande.
Howard Farley Jr., who spent 35 years on the run, was arrested in a tiny town in Florida as he was attempting to board his private plane in the hangar at his home.
"For 500 million, I am very comfortable we are gonna get there (2021)," Bancel said, while speaking at the Nasdaq Investor Conference. The CEO said the company will be able to maintain a premium price of $37 for its vaccine doses.
With the political opponents of President Nicolás Maduro boycotting Sunday's election for the National Assembly, his socialist party is expected to dominate the vote, giving him control of the last major institution in Venezuela outside his grasp. Both votes are playing out in the waning days of the Trump administration, which leaves office with Maduro firmly entrenched despite its efforts to bring about his departure through diplomacy and sanctions.
Robert Saleh "would help us reach peaks that have seemed unobtainable for so long," the group wrote in an open letter.
Former Ivory Coast president Laurent Gbagbo, who was forced from power after losing elections 10 years ago, has obtained a new passport and plans to return home this month, his lawyer said on Friday.
Shares of special purpose acquisition company (SPAC) Star Peak Energy Transition (NYSE: STPK) rocketed up today after the company revealed its investment target. Star Peak said it will combine with Stem, a smart energy storage company, to create a new public company that will be listed on the New York Stock Exchange under the new symbol STEM. Stem uses artificial intelligence (AI) to optimize clean energy assets and supplies its customers with digitally connected storage networks.
The Synthetic Gypsum Market will grow by $ 319.51 mn during 2020-2024
TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: OSB GROUP PLC 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer2\. Reason for the notification (please mark the appropriate box or boxes with an “X”) An acquisition or disposal of voting rightsX An acquisition or disposal of financial instrumentsAn event changing the breakdown of voting rightsOther (please specify)iii:3\. Details of person subject to the notification obligationiv Name ELEVA CAPITAL SAS City and country of registered office (if applicable) FRANCE 4\. Full name of shareholder(s) (if different from 3.)v Name ELEVA UCITS FUND City and country of registered office (if applicable) LUXEMBOURG 5\. Date on which the threshold was crossed or reachedvi: 30/11/2020 6\. Date on which issuer notified (DD/MM/YYYY): 04/12/2020 7\. Total positions of person(s) subject to the notification obligation% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights of issuervii Resulting situation on the date on which threshold was crossed or reached 2.324% 0.996% 3.320% 447 304 198Position of previous notification (if applicable) 0% 0% 0% 8\. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii A: Voting rights attached to shares Class/type of shares ISIN code (if possible)Number of voting rightsix% of voting rights Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1)Direct (Art 9 of Directive 2004/109/EC) (DTR5.1)Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) GB00BM7S7K96 10 394 400 2.324% SUBTOTAL 8. A10 394 4002.324% B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR18.104.22.168 (a)) Type of financial instrumentExpiration datexExercise/ Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is exercised/converted.% of voting rights SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR22.214.171.124 (b)) Type of financial instrumentExpiration datexExercise/ Conversion Period xiPhysical or cash settlementxiiNumber of voting rights % of voting rights CFDN/AN/ACash-settlement 4 456 900 0.996% SUBTOTAL 8.B.2 4 456 900 0.996% 9\. Information in relation to the person subject to the notification obligation (please mark the applicable box with an “X”) Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)X Namexv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold Eleva Capital Partners UK Limited ELEVA CAPITAL SAS2.324%0.996%3.320% 10\. In case of proxy voting, please identify: Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held 11\. Additional informationxvi ELEVA CAPITAL SAS, a French asset manager, holds through the portfolios it manages 3.320% of OSB GROUP PLC. Place of completionLondon Date of completion04/12/2020
Queen of video calls!
In a year short on new cinematic releases, the premise for Amazon Studios’ upcoming film I’m Your Woman sounds mighty intriguing: a thriller set in the ’70s in which powerful female characters join forces to take on crime bosses. Actress Marsha Stephanie Blake plays Teri, one of these badass women, who unwittingly finds herself on the run after being pulled back into a world she thought she’d successfully escaped. Here’s what makes Blake feel powerful, including the real-life acts of courage she called on for her latest role: I feel most powerful when… I’m playing a person whose power comes from extreme sacrifice, extreme love, extreme commitment. I guess in a nutshell I’m saying my power comes from my work. Even more so when I’m playing a real person, but not necessarily. It’s something that’s hard to evaluate. It is such an emotional thing, as hard to pinpoint as it is to quantify. Power to me means.. Being so comfortable in your own skin that you don’t feel like you need to fill silence — that, in fact, your silence speaks volumes. What do you do when you feel powerless? I usually get very chatty, trying to overcome any feeling of discomfort or inadequacy with words. What’s your power anthem? “It’s all gonna be okay” is what I repeat on most days because I do believe you can manifest positivity by speaking positively. But if we’re talking songs it’s probably “Ride Natty Ride” by Bob Marley. Who is your power icon? I’m a big believer that still waters run deep, so I have seen powerful acts of love and restraint and resilience from some of the most quiet women in my life. It’s those women that I based the character Teri in I’m Your Woman on: my mom, my aunts. But if we mean someone famous, Ava Duvernay. What do you wear when you want to feel powerful? I’m super into gorgeous, rich fabrics. So sometimes it’s not the style of clothes so much as what it’s made out of. And I’m a sucker for good tailoring. But let’s say I’m walking out the house to a meeting during which I want to feel like a badass — I’d probably rock a white pantsuit, high heels, eyelashes. I’m Your Woman launches on Amazon Prime Video on December 11. Watch the official trailer below. Like what you see? How about some more R29 goodness, right here?
PLANO, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,000,000 shares by the Company of its Class A common stock, at a price to the public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional shares of its Class A common stock, on the same terms and conditions as the shares offered in the public offering. Barclays Capital Inc. and Goldman Sachs & Co. LLC acted as the joint book-running managers for the offering.The securities described above were offered pursuant to an automatically effective shelf registration statement on Form S-3. The offering was conducted only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the Securities and Exchange Commission (the “SEC”) and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by request at Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 1-888-603-5847, or by emailing Barclaysprospectus@broadridge.com; or Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectusfirstname.lastname@example.org.This news release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Reata Pharmaceuticals, Inc.Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.Forward-Looking StatementsThis press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the public offering and the anticipated use of net proceeds of the offering, the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, our plans to submit regulatory filings, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans,” “model,” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (i) the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all; (ii) the timing, costs, conduct, and outcome of our clinical trials and future preclinical studies and clinical trials, including the timing of the initiation and availability of data from such trials; (iii) the timing and likelihood of regulatory filings and approvals for our product candidates; (iv) whether regulatory authorities determine that additional trials or data are necessary in order to obtain approval; (v) the potential market size and the size of the patient populations for our product candidates, if approved for commercial use, and the market opportunities for our product candidates; and (vi) other factors set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Contact: Reata Pharmaceuticals, Inc. (972) 865-2219Investor Relations: Vinny Jindal (469) 374-8721 email@example.com